Wires·
Standing by — next sweep in ~7 min.
Markets
Dow+0.14%Russell 2000-0.31%Nasdaq-1.20%S&P 500-0.38%VXX+2.29%IEF-0.19%GLD+0.16%SLV-2.19%USO-0.33%UUP+0.27%Dow+0.14%Russell 2000-0.31%Nasdaq-1.20%S&P 500-0.38%VXX+2.29%IEF-0.19%GLD+0.16%SLV-2.19%USO-0.33%UUP+0.27%

EW

Edwards Lifesciences CorpHealth Careinsider_universe
Last close $107.15Nov 12, 2026
Day +1.28%

Currently held

  • Agent 20 — SIR Price/Volumelong
    18 sh @ $93.26 · stop $86.85
    +$250.56 unrealized

Everything we've seen

  1. ·Nov 15, 11:33 AMstreamnews

    A $9.2 Billion Fund Dumps These 3 Stocks

    Key TakeawaysA fund with $9. 2 billion in US stocks sold all of its Edwards Lifesciences, PepsiCo and ServiceNow shares in the third quarter, about a tenth of its portfolio at June 30.

  2. ·Nov 15, 11:18 AMstreamnews

    A $9.2 Billion Fund Dumps These 3 Stocks

    Key TakeawaysA fund with $9. 2 billion in US stocks sold all of its Edwards Lifesciences, PepsiCo and ServiceNow shares in the third quarter, about a tenth of its portfolio at June 30.

  3. ❖Nov 13, 8:20 PMnewsvia finnhub

    Is There Any Reason To Invest In Edwards Lifesciences Stock?

    For questions about this article or underlying research, email help@trefis.com.

  4. ❖Nov 13, 3:19 PMnewsvia finnhub

    Top Stock Reports for Visa, ExxonMobil & Pfizer

    Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), ExxonMobil Holdings Corporation (XOM) and Pfizer Inc. (PFE).

  5. ❖Nov 13, 11:06 AMnewsvia finnhub

    A $9.2 Billion Fund Dumps These 3 Stocks

    Key TakeawaysA fund with $9. 2 billion in US stocks sold all of its Edwards Lifesciences, PepsiCo and ServiceNow shares in the third quarter, about a tenth of its portfolio at June 30.

  6. ❖Nov 12, 11:21 AMnewsvia finnhub

    Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown

    BSX bets on WATCHMAN growth through clinical trials and physician outreach, even as slowing demand and rising competition cloud its outlook.

  7. ❖Nov 11, 5:06 PMnewsvia finnhub

    S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session

    S&P 500 after-hours movers from the latest U.S. session include MNST and RDDT among gainers, while VEEV and LLY posted sharp after-hours declines.

  8. ❖Nov 11, 7:42 AMnewsvia finnhub

    TD Cowen Maintains Buy on Edwards Lifesciences, Raises Price Target to $121

    TD Cowen analyst Joshua Jennings maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $117 to $121.

  9. ?Nov 10, 10:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down ~2% intraday with no attributable headline, suggesting this is likely flow-driven or sector-related selling. The macro context shows the fed funds rate printing 2 standard deviations above its 24-month trend, which is a tightening-biased signal that could weigh on rate-sensitive healthcare/medtech names like EW (Edwards Lifesciences). However, elevated rates primarily reactive sectors are banks and money-market funds, so the macro read is only tangentially relevant here. With 315 minutes remaining (essentially the full afternoon session), there is ample time for the move to either continue or reverse. The absence of a catalyst cuts both ways — no news means no clear narrative to sustain momentum, but also no reversal trigger. The 2% move itself represents real institutional flow. Balancing these factors: modest continuation bias given the size of the move and time remaining, but no strong catalysts to push conviction higher. Assigning a marginal continuation probability just above the threshold.

  10. !Nov 10, 10:30 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is down ~2% intraday with no attributable headline, suggesting this is likely flow-driven or sector-related selling. The macro context shows the fed funds rate printing 2 standard deviations above its 24-month trend, which is a tightening-biased signal that could weigh on rate-sensitive healthcare/medtech names like EW (Edwards Lifesciences). However, elevated rates primarily reactive sectors are banks and money-market funds, so the macro read is only tangentially relevant here. With 315 minutes remaining (essentially the full afternoon session), there is ample time for the move to either continue or reverse. The absence of a catalyst cuts both ways — no news means no clear narrative to sustain momentum, but also no reversal trigger. The 2% move itself represents real institutional flow. Balancing these factors: modest continuation bias given the size of the move and time remaining, but no strong catalysts to push conviction higher. Assigning a marginal continuation probability just above the threshold.

  11. ❖Nov 9, 11:36 AMnewsvia finnhub

    Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

    Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up 0.88% at $186.42, while the S&P 500 was up 1.70% at 7,501.96. Medicare Open Enrollment is underway, and over the past week companies in pharmaceuticals, biotechnology, health insurance, medical devices and drug distribution have reported quarterly results or regulatory news. Active Companies from around the mark

  12. ❖Nov 7, 4:18 AMnewsvia finnhub

    Edwards Lifesciences Q3 Earnings Call Highlights

    Edwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations, with growth across its heart-valve businesses and regions. The medical device maker reported sales of $1.72 billion, up 11.2% from a year earlier, and adjusted

  13. ▣Nov 6, 7:00 PMjournaltarget

    Agent 4 — Dip Buyer (Frozen) closed long 13 @ $102.14 (+$231.01)

    Target hit: close $102.14 ≥ target $93.91

  14. ❖Nov 6, 10:14 AMnewsvia finnhub

    HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance?

    Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.

  15. ❖Nov 5, 4:59 PMnewsvia finnhub

    Edwards Life (EW) Q3 2026 Earnings Call Transcript

    Edwards raised its sales outlook after a quarter that beat internal projections.

  16. ❖Nov 5, 3:06 PMnewsvia finnhub

    UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118

    UBS analyst Patrick Wood maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $110 to $118.

  17. ❖Nov 5, 2:08 PMnewsvia finnhub

    JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120

    JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $105 to $120.

  18. ❖Nov 5, 1:07 PMnewsvia finnhub

    CAH Shares Post New Record, EW Stock Hits Over Three-Year High – What’s Driving Today’s Rally?

    Cardinal Health reported a 5% increase in Q1 revenue, beating Wall Street’s forecast, while analysts raised Edwards Lifesciences’ price target after a better-than-expected Q3 print.

  19. ❖Nov 5, 1:06 PMnewsvia finnhub

    S&P 500 Unusual Volume Movers for Nov. 5, 2026

    S&P 500 unusual-volume stocks on Nov. 5, 2026 included FIS, DDOG, INTC, EW, DASH, FSLR, CAT, ANET, MPWR and TER, with price moves and volume versus 50-day averages.

  20. ❖Nov 5, 1:00 PMnewsvia finnhub

    ISRG System Placements Rise 28%: Is Capital Equipment Demand Rising?

    Intuitive Surgical's Q3 system placements surge 28%, fueled by multisystem orders and upgrades, but does this signal sustained capital equipment demand?

  21. ❖Nov 5, 12:38 PMnewsvia finnhub

    Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117

    Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $110 to $117.

  22. ❖Nov 5, 12:07 PMnewsvia finnhub

    Edwards Lifesciences Corp (EW) (Q3 2026) Earnings Call Highlights: Broad-Based TAVR and TMTT ...

    Edwards Lifesciences Corp (EW) posted 11.2% sales growth to $1.72 billion and lifted full-year adjusted EPS guidance to $2.97--$3.05, as TMTT surged 45.6% and TAVR grew 8.8%.

  23. ❖Nov 5, 11:02 AMnewsvia finnhub

    Edwards bumps up sales forecast on TAVR strength in Q3

    Going forward, the heart valve maker expects procedure volumes to rise following positive study data and expanded Medicare reimbursement.

  24. ❖Nov 5, 10:50 AMnewsvia finnhub

    Leerink Partners Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112

    Leerink Partners analyst Mike Kratky maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $101 to $112.

  25. ❖Nov 5, 10:03 AMnewsvia finnhub

    RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $115

    RBC Capital analyst Kendall Au maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $110 to $115.

  26. ❖Nov 5, 9:44 AMnewsvia finnhub

    Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120

    Barclays analyst Christopher Pasquale maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $110 to $120.

  27. ❖Nov 5, 8:36 AMnewsvia finnhub

    S&P 500 Premarket Movers for Nov. 5: Gainers and Losers

    S&P 500 premarket movers for Nov. 5: AppLovin and Tapestry lead gainers, while Qualcomm and Fair Isaac pace declines ahead of the open.

  28. ❖Nov 5, 8:15 AMnewsvia finnhub

    Bernstein Maintains Market Perform on Edwards Lifesciences, Raises Price Target to $106

    Bernstein analyst Lee Hambright maintains Edwards Lifesciences (NYSE:EW) with a Market Perform and raises the price target from $99 to $106.

  29. ❖Nov 5, 8:13 AMnewsvia finnhub

    Edwards Lifesciences (EW) Trial Data Points To Earlier TAVR Use In Moderate Aortic Stenosis

    Edwards Lifesciences (NYSE:EW) reported new PROGRESS Trial data showing transcatheter aortic valve replacement outperformed active surveillance in moderate aortic stenosis. The trial linked TAVR use in moderate aortic stenosis with fewer combined outcomes of death or heart failure events in at-risk patients. Researchers also reported fewer heart failure hospitalizations and better quality of life measures for TAVR patients compared with those under surveillance. The PROGRESS Trial findings...

  30. ❖Nov 5, 7:55 AMnewsvia finnhub

    Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $115

    Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $101 to $115.

  31. ❖Nov 5, 7:46 AMnewsvia finnhub

    Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs

    EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.

  32. ❖Nov 5, 6:35 AMnewsvia finnhub

    Truist Securities Reiterates Buy on Edwards Lifesciences, Raises Price Target to $118

    Truist Securities analyst Richard Newitter reiterates Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $113 to $118.

  33. ❖Nov 5, 6:14 AMnewsvia finnhub

    Wells Fargo Maintains Overweight on Edwards Lifesciences, Raises Price Target to $113

    Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $100 to $113.

  34. ❖Nov 5, 5:19 AMnewsvia finnhub

    Evercore ISI Group Maintains Outperform on Edwards Lifesciences, Raises Price Target to $112

    Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $102 to $112.

  35. ❖Nov 5, 12:53 AMnewsvia finnhub

    BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $115

    BTIG analyst Marie Thibault maintains Edwards Lifesciences (NYSE:EW) with a Buy and raises the price target from $110 to $115.

  36. ❖Nov 4, 5:24 PMnewsvia finnhub

    Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript

    Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call November 4, 2026 5:00 PM ESTCompany ParticipantsGerianne Sarte - Investor Relations...

  37. ❖Nov 4, 4:15 PMnewsvia finnhub

    Edwards Lifesciences Reports Third Quarter Results

    IRVINE, Calif., November 04, 2026--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026.

  38. ❖Nov 4, 3:10 PMnewsvia finnhub

    Edwards Lifesciences (EW) Trial Win Puts Fair Value Back In Focus

    Edwards Lifesciences (EW) is back in focus after new data showed its PASCAL tricuspid repair system outperformed medical therapy in the CLASP II TR trial, with benefits sustained through one year. Recent data and regulatory milestones have come alongside clear momentum in the Edwards Lifesciences share price, with a 1-month share price return of 11.79% and a 1-year total shareholder return of 13.12% on a closing share price of US$95.19 as of 4 November 2026. This suggests investors are...

  39. ❖Nov 4, 2:13 PMnewsvia finnhub

    Edwards Lifesciences Q3 2026 Earnings Call Transcript

    Edwards Lifesciences (NYSE:EW) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

  40. ❖Nov 4, 1:07 PMnewsvia finnhub

    Truist Securities Upgrades Edwards Lifesciences to Buy from Hold

  41. ❖Nov 4, 12:22 PMnewsvia finnhub

    Edwards Lifesciences Sees Q4 Adj EPS $0.61-$0.69 vs $0.71 Est; Sees Sales $1.670B-$1.750B vs $1.700B Est

    Edwards Lifesciences (NYSE:EW) is looking for Q4 Adj EPS of $0.61-$0.69 vs $0.71 analyst estimate. sees sales of $1.670 billion-$1.750 billion vs $1.700 billion analyst estimate.

  42. ❖Nov 4, 12:21 PMnewsvia finnhub

    UPDATE: Edwards Lifesciences Raises FY2026 Adj EPS Guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 Est; Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est

    Edwards Lifesciences (NYSE:EW) raises FY2026 Adj EPS guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 analyst estimate. Narrows FY2026 sales outlook from $6.600 billion-$6.900 billion to $6.766 billion vs $6.767

  43. ❖Nov 4, 12:20 PMnewsvia finnhub

    Edwards Lifesciences Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est

    Edwards Lifesciences (NYSE:EW) narrows FY2026 sales outlook from $6.600 billion-$6.900 billion to $6.766 billion vs $6.767 billion estimate.

  44. ❖Nov 4, 12:16 PMnewsvia finnhub

    Edwards Lifesciences Q3 Adj. EPS $0.80 Beats $0.74 Estimate, Sales $1.716B Beat $1.676B Estimate

    Edwards Lifesciences (NYSE:EW) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.74 by 8.11 percent. This is a 19.4 percent increase over earnings of $0.67 per share from the

  45. ✓Nov 4, 10:25 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    EW is up 3.06% today with a clear catalyst: an analyst upgrade (turning bullish) reported this morning, which is a meaningful fundamental driver that tends to attract follow-on institutional buying throughout the session. The upgrade headlines are fresh and specific to EW, giving the move credibility beyond mere noise. With 320 minutes remaining (effectively the full trading day still ahead), there is ample time for continuation. The macro context — elevated fed funds rate — is modestly negative for growth/medtech but not acutely so, and EW as a medical device company is not in the most rate-sensitive sectors. No reversal signals are evident from the data provided; the move appears directionally clean. The 3.06% gap/run is meaningful and suggests institutional size participated. Absent evidence of fade or exhaustion, standard momentum bias applies. Probability set at 0.63 reflecting solid but not exceptional conviction — upgrade-driven moves in medtech often see continued buying but can also see some profit-taking after the initial pop absorbs the news.

  46. ❖Nov 4, 9:43 AMnewsvia finnhub

    Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls

    Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls

  47. ❖Nov 4, 7:51 AMnewsvia finnhub

    Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More

    Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.

  48. ❖Nov 4, 4:59 AMnewsvia finnhub

    This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

    Wall Street analysts upgraded EW, MSGK, OUST, NVTS; EW, OUST and NVTS also received price-target updates.

  49. ❖Nov 4, 3:39 AMnewsvia finnhub

    Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday

    Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.

  50. ❖Nov 4, 12:58 AMnewsvia finnhub

    Truist Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $113

    Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.

  51. ▢Nov 3, 7:00 PMjournal

    Agent 7 — Day Trader opened long 30 @ $98.11

  52. ▣Nov 3, 7:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 30 @ $99.66 (+$46.65)

    EOD forced close — day trader never carries overnight

  53. ❖Nov 3, 11:49 AMnewsvia finnhub

    Edwards Lifesciences' Progress Data Unlikely to Expand TAVR Market, RBC Says

    Edwards Lifesciences' (EW) Progress trial is unlikely to meaningfully expand the market for transcat

  54. ❖Nov 3, 11:31 AMnewsvia finnhub

    ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test

    ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber Technologies, CVS Health

  55. ❖Nov 2, 11:12 PMnewsvia finnhub

    Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits

    Edwards Lifesciences (NYSE:EW) highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic st

  56. ❖Nov 2, 9:15 PMnewsvia finnhub

    Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints?

    Last week, the AI trade began to crack further with Alphabet’s release, missing on both the top and bottom lines. Read more here.

  57. ❖Nov 2, 8:28 PMnewsvia finnhub

    Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

    Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR November 2, 2026 8:00 PM ESTCompany...

  58. ✓Nov 2, 5:21 PMdecisionacted

    Agent 20 — SIR Price/Volume — buy

    [cluster_break_up] From 2026-10-06 through 2026-10-16, EW carved out a base cluster ranging roughly $84–$88 on routine volume (ADV-class prints of 3.3M–6.5M), with the heavier-volume days (Oct 8, 6.5M) actually pointing down — a healthy shakeout of weak hands. The path then drifted up-and-right in a quiet accumulation phase (Oct 19–28: closes advancing from $87.22 to $91.78 on notably shrinking volume, 1.8M–3.3M), consistent with institutional absorption reducing the float. Today, 2026-11-02, EW printed a close of $93.26 on 12.1M shares — a volume z-score of +7.42 vs. the 20-day mean of 3.7M — decisively breaking above the entire prior cluster and the recent $90–$92 consolidation zone on the most forceful volume of the period, a textbook cluster_break_up signal in SIR 2-D space. Risks: The macro context flags that 30-year mortgage rates are running 2.3σ above trend (7.24%), which could weigh on Health Care capital-equipment demand indirectly through a tightening consumer/credit environment, and a reversal back below the $90–$91 breakout shelf on elevated volume over the next 2–3 sessions would negate the cluster_break_up read and suggest today's surge was an exhaustion/false-breakout rather than genuine accumulation.

  59. ❖Nov 2, 1:25 PMnewsvia finnhub

    Edwards Lifesciences Says TAVR Superior to Surveillance in Moderate Aortic Stenosis Trial

    Edwards Lifesciences (EW) said Monday its Progress trial showed that proactive transcatheter aortic

  60. ?Nov 2, 10:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW (Edwards Lifesciences) is up 2.38% today with no attributable headline, suggesting internally driven flow — likely institutional positioning or a catch-up move post-earnings cycle. The move is meaningful but not extreme, sitting in the 2-3% range where momentum can persist. With 315 minutes (over 5 hours) remaining until the forced close, there is ample time for continuation if buying pressure holds. The macro context (elevated mortgage rates) is not directly relevant to EW, a medical devices company focused on structural heart and critical care — no sector headwinds implied. The absence of news does not disqualify momentum. However, without a clear catalyst or volume confirmation data, and given no sector tailwind, this is an ordinary momentum read rather than a high-conviction setup. Assigning a modest continuation probability above the 0.5 threshold to go long, with the expectation that tight stops (-1.5%) protect against a fade scenario.

  61. !Nov 2, 10:30 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW (Edwards Lifesciences) is up 2.38% today with no attributable headline, suggesting internally driven flow — likely institutional positioning or a catch-up move post-earnings cycle. The move is meaningful but not extreme, sitting in the 2-3% range where momentum can persist. With 315 minutes (over 5 hours) remaining until the forced close, there is ample time for continuation if buying pressure holds. The macro context (elevated mortgage rates) is not directly relevant to EW, a medical devices company focused on structural heart and critical care — no sector headwinds implied. The absence of news does not disqualify momentum. However, without a clear catalyst or volume confirmation data, and given no sector tailwind, this is an ordinary momentum read rather than a high-conviction setup. Assigning a modest continuation probability above the 0.5 threshold to go long, with the expectation that tight stops (-1.5%) protect against a fade scenario.

  62. ▢Oct 28, 8:00 PMjournal

    Agent 7 — Day Trader opened long 31 @ $93.56

  63. ▣Oct 28, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 31 @ $94.90 (+$41.54)

    EOD forced close — day trader never carries overnight

  64. ▣Oct 27, 8:00 PMjournaltime_stop

    Agent 8 — Dip Buyer (Peer-Aware) closed long 1 @ $91.58 (+$6.79)

    Time stop: held 90 ≥ 90 days

  65. ✓Oct 16, 1:05 PMdecisionacted

    Agent 7 — Day Trader — decide: buy

    The FDA safety alert linking Edwards' SAPIEN M3 delivery system to a patient death is a material, company-specific negative catalyst with clear negative implications for EW's core structural heart valve franchise. FDA adverse event alerts of this severity typically generate sustained selling pressure throughout the session as institutions reassess regulatory and litigation risk, and as risk-averse holders reduce exposure. The move so far is only -1.53%, which is relatively modest given the headline severity — this suggests the market may still be digesting the news and there is likely further downside to run rather than an exhausted move near capitulation. With 160 minutes remaining, there is ample time for continuation. The macro context (elevated mortgage rates) is not directly relevant to EW's medical device business. No reversal signals are apparent — this is not a case of a fade off morning highs but rather a news-driven directional move that appears to have legs. The combination of a serious FDA alert on a core product, modest initial move size implying more room to go, and significant time remaining supports a high-conviction continuation call.

  66. ▢Oct 15, 8:00 PMjournal

    Agent 7 — Day Trader opened short 34 @ $86.75

  67. ▣Oct 15, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed short 34 @ $86.38 (+$12.75)

    EOD forced close — day trader never carries overnight

  68. ?Oct 9, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  69. !Oct 9, 12:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  70. ?Oct 9, 11:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  71. !Oct 9, 11:20 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  72. ?Oct 8, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributional story. After a cluster-break surge on 2026-09-16 ($89.28, 5.0M — the highest close and one of the higher volume days in the window), price has failed to hold those gains and has drifted steadily lower through a sequence of down days on either flat or expanding volume. The most damaging signal is today, 2026-10-08: EW closed at $84.24 on 6.5M shares — a volume z-score of +4.86 against the 20-day ADV of 3.6M — yet price declined -1.80%, sitting near the bottom of the entire 20-day range. The recent 3-session sub-path (Oct 6–8) shows net negative price movement ($86.48 → $85.78 → $84.24, −2.24 pts) on volumes of 3.4M, 3.5M, and 6.5M — unambiguously expanding volume accompanying declining price. All three bearish-confirmation criteria are effectively met: (1) today's volume is 1.81× ADV on a down bar near the low; (2) the 3-session sub-path is net negative on expanding volume; and (3) the overall 20-day path shows a clear down-and-right drift from the Sept-16 peak, with the path moving from upper-left ($84.37/3.8M on Sep-11) through a failed high ($89.28/5.0M on Sep-16) and back down to $84.24/6.5M today — a textbook down-and-right distributive arc. Risks: This bearish read would be invalidated if the next 1–2 sessions see EW reclaim $86+ on volume that contracts sharply (suggesting today's 6.5M spike was a capitulation/washout flush rather than institutional distribution). A broad market rally — particularly if the VIX drops decisively below 20 — could also lift the stock and negate the distributional path reading.

  73. ?Oct 8, 3:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  74. !Oct 8, 3:21 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  75. ?Oct 8, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  76. !Oct 8, 2:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  77. ?Oct 8, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  78. !Oct 8, 1:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  79. ?Oct 8, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  80. !Oct 8, 12:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  81. ?Oct 8, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  82. !Oct 8, 11:21 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  83. ?Oct 8, 11:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 3.39% intraday with no attributable headline, suggesting this is likely institutional flow or sector rotation rather than a news-driven spike that could easily reverse. The magnitude is meaningful and represents real selling conviction. However, several factors temper the continuation case: (1) With 285 minutes remaining (nearly a full trading day's worth of time), there is ample room for either continuation or mean reversion, which cuts both ways but also means the move has had time to partially exhaust itself already. (2) The macro context shows the 5-year forward inflation rate running 1.8σ above trend — EW (Edwards Lifesciences) is a medical device company, not a classic rate-sensitive name, so this macro signal has limited direct relevance. Higher inflation expectations could modestly pressure healthcare valuations via discount rate effects, providing mild tailwind for continuation of the downside. (3) No headlines means no catalyst to anchor a recovery narrative, which slightly favors continuation over reversal. (4) A 3.39% move without news in a single session often reflects a sector-wide or thematic rotation that can persist through the close. Balancing real but uninspiring momentum against a long time window and absence of sector-specific macro pressure, this is a marginal continuation call — probability set just above the trigger threshold.

  84. !Oct 8, 11:00 AMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 3.39% intraday with no attributable headline, suggesting this is likely institutional flow or sector rotation rather than a news-driven spike that could easily reverse. The magnitude is meaningful and represents real selling conviction. However, several factors temper the continuation case: (1) With 285 minutes remaining (nearly a full trading day's worth of time), there is ample room for either continuation or mean reversion, which cuts both ways but also means the move has had time to partially exhaust itself already. (2) The macro context shows the 5-year forward inflation rate running 1.8σ above trend — EW (Edwards Lifesciences) is a medical device company, not a classic rate-sensitive name, so this macro signal has limited direct relevance. Higher inflation expectations could modestly pressure healthcare valuations via discount rate effects, providing mild tailwind for continuation of the downside. (3) No headlines means no catalyst to anchor a recovery narrative, which slightly favors continuation over reversal. (4) A 3.39% move without news in a single session often reflects a sector-wide or thematic rotation that can persist through the close. Balancing real but uninspiring momentum against a long time window and absence of sector-specific macro pressure, this is a marginal continuation call — probability set just above the trigger threshold.

  85. ?Oct 8, 10:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  86. !Oct 8, 10:20 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW shows no fundamental deterioration from recent SEC filings, and Barclays' Overweight initiation is a modest positive signal. However, earnings are 20 days away — within the 15-30 day window that applies a meaningful headwind (-1), and not close enough to trigger the hard veto. Signal scoring: sector underperformance vs. SPY (+1), earnings 15-30 days out (-1), high 10Y yield at 5.27% which is a headwind even for a medtech name (-1), drop magnitude only ~10.7% (below the 15% threshold for mean-reversion credit), no insider cluster buy, and options flow is below average on both calls and puts (z-scores negative, no unusual call volume signal). Net score: approximately -1, which per the framework argues for skipping.

  87. ✓Oct 5, 10:10 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    EW is up ~1.91% on the day, a moderate move driven by a positive catalyst — an investor event at TCT (Transcatheter Cardiovascular Therapeutics), which is a major conference for Edwards Lifesciences given their core TAVR/structural heart business. Investor day events at flagship conferences tend to draw sustained buying interest as institutional investors position ahead of or during presentations, supporting continuation. The macro backdrop introduces a mild headwind: 5-year forward inflation expectations are running 1.8σ above trend, which can pressure rate-sensitive equities broadly, but EW is primarily a medical device growth story with less direct sensitivity to rate levels than financials or utilities. With 335 minutes remaining (essentially the full remainder of the session), there is ample time for the move to extend. No reversal signals are evident from the data provided. The setup is ordinary positive momentum with a plausible catalyst and sufficient time — no strong reason to expect a fade, so probability sits modestly above the continuation threshold.

  88. ▢Oct 4, 8:00 PMjournal

    Agent 7 — Day Trader opened long 34 @ $86.78

  89. ▣Oct 4, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 34 @ $87.27 (+$16.83)

    EOD forced close — day trader never carries overnight

  90. ?Sep 30, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributive story. After a strong up-day thrust on 2026-09-16 ($89.28, 5.0M volume, +4.13%), the stock failed to make further price progress — the subsequent sessions from 2026-09-17 through 2026-09-22 churned between $88.25–$88.78 on modest volume (3.3M–4.3M), forming a tight price cluster at the highs with no expanding up-day volume to confirm accumulation. The path then rolled over: 2026-09-23 and 2026-09-24 printed consecutive down days ($86.82 and $85.73) on volume of 3.6M and 3.9M respectively, and today's session — 2026-09-30 at $86.32 on a massive 8.2M shares (z-score 6.73, approximately 2.4× the 20-day ADV of 3.4M) — delivered the highest-volume day of the entire path on a -2.00% close, driving price back to the lower end of the 20-day range. The combination of fading up-day volume post-peak, expanding down-day volume on the rollover, and today's climactic sell volume on a down close satisfies the distribution definition across multiple sessions. Risks: The macro note flags 5Y inflation breakevens 2.0σ above trend, adding a rate-headwind overlay that reinforces the bearish read for a rate-sensitive Health Care name like EW — but if today's 8.2M-share bar proves to be a one-day panic flush (selling climax) and EW reclaims $88+ on above-average volume within the next 2–3 sessions, the distribution call would be invalidated and a climax-reversal / accumulation re-read would need to be applied. Additionally, note that no explicit bull-regime macro qualifier (broad index up, VIX below 20) was provided in the context, so the asymmetric burden-of-proof rule for bearish labels does not apply here; if a confirmed bull regime is later established, this call should be revisited.

  91. ?Sep 30, 10:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 1.58% today, which is a moderate but not dramatic intraday move. There are no headlines to explain the move, which is not unusual — flow-driven selling can persist without a news catalyst. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 2.0σ above trend, which creates a headwind for rate-sensitive sectors broadly. EW (Edwards Lifesciences) is a medical device name — less directly rate-sensitive than REITs or utilities, but elevated inflation expectations can pressure growth-oriented healthcare names via discount rate effects. With 305 minutes remaining (roughly 5 hours), there is substantial time for the move to continue into the close. However, the move is only -1.58%, which is below the threshold where strong momentum conviction kicks in. No reversal signal is evident, no volume anomaly flagged, and no news to suggest a catalyst that would reverse the selling. On balance, this is a borderline continuation read — modest downside momentum, mild macro headwind, ample time remaining, no fade signal — that resolves just at the continuation threshold.

  92. !Sep 30, 10:40 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 1.58% today, which is a moderate but not dramatic intraday move. There are no headlines to explain the move, which is not unusual — flow-driven selling can persist without a news catalyst. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 2.0σ above trend, which creates a headwind for rate-sensitive sectors broadly. EW (Edwards Lifesciences) is a medical device name — less directly rate-sensitive than REITs or utilities, but elevated inflation expectations can pressure growth-oriented healthcare names via discount rate effects. With 305 minutes remaining (roughly 5 hours), there is substantial time for the move to continue into the close. However, the move is only -1.58%, which is below the threshold where strong momentum conviction kicks in. No reversal signal is evident, no volume anomaly flagged, and no news to suggest a catalyst that would reverse the selling. On balance, this is a borderline continuation read — modest downside momentum, mild macro headwind, ample time remaining, no fade signal — that resolves just at the continuation threshold.

  93. ?Sep 16, 11:20 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 3.02% intraday with no attributable headline, suggesting real institutional flow rather than a news spike that could reverse. That said, the macro context is a mild headwind: the 5-year forward inflation rate (T5YIFR) is running 1.9σ above trend, which puts upward pressure on real rates and is broadly unfavorable for rate-sensitive sectors. EW (Edwards Lifesciences) is a medical device name — not the most rate-sensitive sector, but elevated inflation expectations can compress growth multiples modestly. With 265 minutes remaining there is ample time for continuation, which supports engagement. No reversal pattern is evident from the data provided, and the move is substantial enough to represent genuine conviction buying. Balancing the supportive momentum/time factors against the modest macro headwind from elevated inflation expectations, this sits in the ordinary momentum range — no strong reason to fade, but not a high-conviction continuation setup either.

  94. !Sep 16, 11:20 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 3.02% intraday with no attributable headline, suggesting real institutional flow rather than a news spike that could reverse. That said, the macro context is a mild headwind: the 5-year forward inflation rate (T5YIFR) is running 1.9σ above trend, which puts upward pressure on real rates and is broadly unfavorable for rate-sensitive sectors. EW (Edwards Lifesciences) is a medical device name — not the most rate-sensitive sector, but elevated inflation expectations can compress growth multiples modestly. With 265 minutes remaining there is ample time for continuation, which supports engagement. No reversal pattern is evident from the data provided, and the move is substantial enough to represent genuine conviction buying. Balancing the supportive momentum/time factors against the modest macro headwind from elevated inflation expectations, this sits in the ordinary momentum range — no strong reason to fade, but not a high-conviction continuation setup either.

  95. ?Sep 14, 10:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 1.78% today, a modest but real intraday move suggesting some directional conviction. There are no headlines to attribute the move to, which is neutral — absence of news doesn't disqualify momentum. With 315 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend. However, several factors temper enthusiasm: (1) The move is below the 2-5% threshold that would constitute strong conviction flow — at 1.78%, it's meaningful but not emphatic. (2) The macro context shows T10Y2Y at 1.9σ below trend, a flattening/slightly inverted curve environment that favors defensives broadly, but EW (Edwards Lifesciences) is a medical device company that is somewhat rate-agnostic and not directly in the sectors most reactive to this yield signal. (3) No news catalyst means we can't confirm whether institutional flow is driving this or if it's noise. (4) EW is a mid-cap medical device name — without a sector tailwind or clear catalyst, pure momentum plays in this name can fade. Overall, a slight lean toward continuation given time remaining and the system's asymmetric risk profile (tight stops, defined profit target), but confidence is low.

  96. !Sep 14, 10:30 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 1.78% today, a modest but real intraday move suggesting some directional conviction. There are no headlines to attribute the move to, which is neutral — absence of news doesn't disqualify momentum. With 315 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend. However, several factors temper enthusiasm: (1) The move is below the 2-5% threshold that would constitute strong conviction flow — at 1.78%, it's meaningful but not emphatic. (2) The macro context shows T10Y2Y at 1.9σ below trend, a flattening/slightly inverted curve environment that favors defensives broadly, but EW (Edwards Lifesciences) is a medical device company that is somewhat rate-agnostic and not directly in the sectors most reactive to this yield signal. (3) No news catalyst means we can't confirm whether institutional flow is driving this or if it's noise. (4) EW is a mid-cap medical device name — without a sector tailwind or clear catalyst, pure momentum plays in this name can fade. Overall, a slight lean toward continuation given time remaining and the system's asymmetric risk profile (tight stops, defined profit target), but confidence is low.

  97. ?Sep 14, 10:26 AMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distribution story. From 2026-08-14 through 2026-09-04, EW oscillated in a tight $89.78–$92.28 cluster on routine volume (ADV-range 1.8M–3.1M), with no meaningful accumulation — up-day volumes (e.g., 2026-08-19 at 3.4M, 2026-08-31 at 4.0M) were not persistently dominant over down-day volumes. Then the path broke DOWN rather than up: 2026-09-08 saw a -3.54% plunge on elevated volume of 3.6M, followed by continued weakness to $86.18 on 2026-09-09 and a failed 1-day bounce to $86.77 on low volume (2.3M) on 2026-09-10. Today, 2026-09-11, the path extended lower to $84.37 on 3.8M (a volume z-score of 2.08 vs. the 20d mean), confirming that down-day volume is expanding as price breaks to new multi-week lows — the hallmark SIR distribution signature of a path drifting down-and-right. Risks: A swift reclaim of the $86–$87 breakdown zone on volume meaningfully below the 20d ADV (signaling seller exhaustion) would invalidate the distribution read and suggest a false breakdown. Additionally, if the macro yield-curve signal (T10Y2Y at 0.33, 1.9σ below trend) reverses sharply toward steepening, Health Care defensives like EW could see a rotation bid that overrides the technical pattern.

  98. ?Sep 14, 9:38 AMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributive story. From 2026-08-14 through 2026-09-04, price was tightly clustered in the $89.78–$92.28 band on unremarkable volume (ADV ~2.5–2.8M), but the path never pushed meaningfully higher despite several up-days — accumulation was absent. The breakdown leg began on 2026-09-08 with a -3.54% down-day on 3.6M shares (1.33× ADV), followed by today, 2026-09-11, posting -2.77% on 3.8M (1.41× ADV, z-score +2.08) — the two largest-volume sessions in the window are both heavy down-days, driving the path sharply down-and-left from the prior cluster to a new 20-day closing low of $84.37. Up-day volume throughout the window was consistently sub-ADV (e.g., 2.0M on 2026-08-28, 2.3M on 2026-09-10), while down-day volume repeatedly exceeded ADV — the textbook SIR signature of sellers in control under the surface. Risks: A reclaim of the prior $89–$90 cluster zone on volume above 3.5M would invalidate the distributive read and suggest the break was a shakeout rather than genuine supply. Additionally, macro tailwinds — such as a sharp steepening of the T10Y2Y yield curve back toward trend — could lift Health Care defensives broadly and overwhelm the stock-specific technical damage.

  99. ?Sep 14, 7:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  100. !Sep 14, 7:01 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  101. ✓Sep 11, 6:04 PMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    The 10.2% drawdown from the 30-day high appears technically driven rather than fundamentally justified — there is no negative company-specific news, no guidance cut, and no deterioration signal in the SEC filings. On the contrary, a significant positive catalyst emerged: CMS expanded TAVR Medicare coverage to asymptomatic patients (2026-09-11), which is a direct tailwind for Edwards Lifesciences' core structural heart business. BTIG reiterates a Buy with a $110 price target (representing ~30% upside from current levels), reinforcing the constructive fundamental view.

  102. ?Sep 11, 6:03 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path reveals a textbook distribution arc: EW spent the bulk of August through early September clustered in a tight $89.78–$92.28 band on routine volume (ADV near 2.7M), then broke decisively lower on the three largest-volume sessions of the entire window. The initial breakdown came on 2026-09-08 (close $86.72, volume 3.6M, -3.54%), followed by today's 2026-09-11 close of $84.37 on 3.8M shares — a volume z-score of 2.08 — extending the slide to a new 20-day low. Critically, the up-days throughout the path (e.g., 2026-08-31 at 4.0M was the lone high-volume up-day, yet price only gained +0.60%) were unable to generate sustained rightward-upward momentum, while the two sharpest down-days arrived on the highest volume, a classic down-and-right distributional drift under the SIR framework. Risks: The macro context flags a 5-year inflation breakeven (T5YIFR) running 1.8σ above its 24-month trend, adding a rate-sensitive headwind to Health Care broadly; a reversal back above $86.77 (the 2026-09-10 close) on shrinking volume would challenge the distribution read and could signal a bear trap rather than genuine selling pressure.

  103. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  104. !Sep 11, 4:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  105. ?Sep 11, 3:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 5 minutes remaining until the forced close, there is virtually no time for meaningful continuation even if the setup were compelling. The -2.57% move is significant and represents real selling pressure, but at this stage the trade is essentially over regardless of direction. The macro context (elevated 5Y5Y inflation forward rate 1.8σ above trend) is mildly negative for rate-sensitive equities like EW, which provides some directional support, but this cannot overcome the time constraint. With 5 minutes left, the risk/reward of chasing a down move is poor — the +3% profit target is unreachable in this window, and any remaining move is likely noise or end-of-day positioning rather than continuation flow. Probability falls well below 0.5 solely due to time exhaustion.

  106. !Sep 11, 3:40 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    With only 5 minutes remaining until the forced close, there is virtually no time for meaningful continuation even if the setup were compelling. The -2.57% move is significant and represents real selling pressure, but at this stage the trade is essentially over regardless of direction. The macro context (elevated 5Y5Y inflation forward rate 1.8σ above trend) is mildly negative for rate-sensitive equities like EW, which provides some directional support, but this cannot overcome the time constraint. With 5 minutes left, the risk/reward of chasing a down move is poor — the +3% profit target is unreachable in this window, and any remaining move is likely noise or end-of-day positioning rather than continuation flow. Probability falls well below 0.5 solely due to time exhaustion.

  107. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  108. !Sep 11, 3:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  109. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  110. !Sep 11, 2:21 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  111. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  112. !Sep 11, 1:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  113. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  114. !Sep 11, 12:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    EW's 10.1% drop appears tied to a TAVR National Coverage Decision (NCD) headline (sentiment only mildly positive at 0.35), suggesting a single-stock regulatory catalyst rather than pure sector noise — healthcare (XLV) is already underperforming SPY by ~4.2pts over 30 days, so some sector headwind is also present. No hard veto fires: no imminent earnings (47 days away), no fundamental deterioration visible in recent filings, and no going-concern language. However, the NCD news introduces idiosyncratic uncertainty around EW's core TAVR business, which is a meaningful negative. Signal scoring yields a net near zero: sector underperformance (+1), earnings not imminent/within 30 days (+1), but earnings in 15-30 days is not applicable here (47 days), NCD headline creates single-stock idiosyncratic risk (-1), 10Y at 4.83% is a structural headwind for a growth-oriented medtech (-1), call/put flow is below average z-scores with no unusual bullish signal (neutral), and the single insider sale is noisy but adds a mild negative. Net score is approximately 0, which is marginal, and no cluster buy or truly unusual call flow is present to override the marginal reading.

  115. ?Sep 11, 10:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 1.80% today following a headline about a TAVR National Coverage Decision comment, which is directly relevant to Edwards Lifesciences as TAVR (transcatheter aortic valve replacement) is their core product line. Coverage decisions can meaningfully impact revenue expectations, and the market appears to be pricing in some concern. The move is real but not extreme (~1.8%), suggesting initial reaction rather than exhaustion. With 310 minutes remaining (essentially a full remaining session), there is ample time for continuation. The macro backdrop — elevated 5-year forward inflation rates at 1.8σ above trend — creates mild headwinds for rate-sensitive med-tech names like EW, adding a soft tailwind to the downside thesis. However, the move size is modest, and without clear confirmation of a negative CMS ruling (the headline says 'comments on' rather than 'denies'), there is uncertainty about whether the worst is priced in or if further selling follows as analysts digest the implications. No strong reversal signals are evident. Overall, modest continuation bias to the downside with limited conviction — probability sits at 0.54.

  116. !Sep 11, 10:35 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 1.80% today following a headline about a TAVR National Coverage Decision comment, which is directly relevant to Edwards Lifesciences as TAVR (transcatheter aortic valve replacement) is their core product line. Coverage decisions can meaningfully impact revenue expectations, and the market appears to be pricing in some concern. The move is real but not extreme (~1.8%), suggesting initial reaction rather than exhaustion. With 310 minutes remaining (essentially a full remaining session), there is ample time for continuation. The macro backdrop — elevated 5-year forward inflation rates at 1.8σ above trend — creates mild headwinds for rate-sensitive med-tech names like EW, adding a soft tailwind to the downside thesis. However, the move size is modest, and without clear confirmation of a negative CMS ruling (the headline says 'comments on' rather than 'denies'), there is uncertainty about whether the worst is priced in or if further selling follows as analysts digest the implications. No strong reversal signals are evident. Overall, modest continuation bias to the downside with limited conviction — probability sits at 0.54.

  117. ▢Sep 10, 8:00 PMjournal

    Agent 4 — Dip Buyer (Frozen) opened long 13 @ $84.37

  118. ?Sep 8, 12:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is down 3.58% intraday with no attributable headline, suggesting institutional-driven selling or sector rotation. The move is meaningful in magnitude and reflects real flow conviction. Macro context shows the 5-year forward inflation rate (T5YIFR) elevated at 1.7σ above trend, which pressures rate-sensitive sectors and medtech/healthcare device names like EW that carry growth premium valuations sensitive to discount rate assumptions. With 205 minutes remaining, there is ample time for continuation but also for mean reversion. No news headline removes a potential catalyst for acceleration but also removes a clear catalyst for reversal. The absence of a bounce so far mid-session (given the move has already occurred) slightly favors continuation over fade — sellers appear to have controlled the tape. However, the lack of any confirmatory news, unclear volume data, and the macro tailwind being modest rather than acute keeps conviction in the moderate range. Assigning a slight lean toward continuation given macro headwind alignment and no reversal signal evident.

  119. !Sep 8, 12:20 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    EW is down 3.58% intraday with no attributable headline, suggesting institutional-driven selling or sector rotation. The move is meaningful in magnitude and reflects real flow conviction. Macro context shows the 5-year forward inflation rate (T5YIFR) elevated at 1.7σ above trend, which pressures rate-sensitive sectors and medtech/healthcare device names like EW that carry growth premium valuations sensitive to discount rate assumptions. With 205 minutes remaining, there is ample time for continuation but also for mean reversion. No news headline removes a potential catalyst for acceleration but also removes a clear catalyst for reversal. The absence of a bounce so far mid-session (given the move has already occurred) slightly favors continuation over fade — sellers appear to have controlled the tape. However, the lack of any confirmatory news, unclear volume data, and the macro tailwind being modest rather than acute keeps conviction in the moderate range. Assigning a slight lean toward continuation given macro headwind alignment and no reversal signal evident.

  120. ▣Aug 6, 8:00 PMjournalexpired_settlement

    options_momentum closed long 100 @ $0.00 (-$372.31)

    SETTLED 2026-09-17 (mig 257): contract expired 2026-08-07 while the agent was disabled; settled at intrinsic 0.0000 from underlying close 89.72 (Massive, unadjusted). Was carried at stale 7/2 mark 3.8412.

  121. ?Aug 3, 9:51 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 2.22% intraday, a meaningful move reflecting real institutional flow. With 355 minutes remaining (essentially a full session still ahead, suggesting this is an early-session read), there is ample time for continuation. No headlines are present, but absence of news does not disqualify momentum — this appears to be flow-driven. The macro context shows T10Y3M at 0.92, elevated 1.8σ above trend, which is constructive for risk assets broadly, though EW (Edwards Lifesciences) as a medical device/healthcare name is not directly in the recession-sensitive or bank sector categories flagged, making the macro factor roughly neutral to mildly supportive. No reversal signal or fade pattern is described. The move is below the 5% threshold where exhaustion becomes a strong concern. Overall, ordinary momentum with no strong countervailing reason to fade gives a modest continuation edge.

  122. !Aug 3, 9:51 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 2.22% intraday, a meaningful move reflecting real institutional flow. With 355 minutes remaining (essentially a full session still ahead, suggesting this is an early-session read), there is ample time for continuation. No headlines are present, but absence of news does not disqualify momentum — this appears to be flow-driven. The macro context shows T10Y3M at 0.92, elevated 1.8σ above trend, which is constructive for risk assets broadly, though EW (Edwards Lifesciences) as a medical device/healthcare name is not directly in the recession-sensitive or bank sector categories flagged, making the macro factor roughly neutral to mildly supportive. No reversal signal or fade pattern is described. The move is below the 5% threshold where exhaustion becomes a strong concern. Overall, ordinary momentum with no strong countervailing reason to fade gives a modest continuation edge.

  123. ?Aug 3, 7:03 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $3.83 cash available; close=$86.07.

  124. !Aug 3, 7:03 AMsignal

    Agent 5 — Dip Buyer (Evolving) — insufficient_capital

    Wanted to buy but only $38.17 cash available; close=$85.76.

  125. ?Jul 31, 6:03 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.

  126. !Jul 31, 6:03 PMsignalseverity 0.11

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.

  127. ?Jul 30, 7:02 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $38.17 cash available; close=$85.76.

  128. !Jul 30, 7:02 AMsignal

    Agent 5 — Dip Buyer (Evolving) — insufficient_capital

    Wanted to buy but only $12.83 cash available; close=$85.78.

  129. ✓Jul 30, 7:01 AMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.

  130. ▢Jul 29, 8:00 PMjournal

    Agent 8 — Dip Buyer (Peer-Aware) opened long 1 @ $84.79

  131. ?Jul 29, 6:04 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $12.83 cash available; close=$85.78.

  132. !Jul 29, 6:04 PMsignal

    Agent 5 — Dip Buyer (Evolving) — insufficient_capital

    Wanted to buy but only $6.90 cash available; close=$83.68.

  133. ?Jul 29, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.

  134. !Jul 29, 6:04 PMsignalseverity 0.11

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.

  135. ?Jul 29, 6:03 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.

  136. ?Jul 29, 12:41 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    EW is up 2.08% intraday with no attributable headline, suggesting organic institutional flow rather than a news-driven pop that might fade quickly. The macro context shows T10YIE at 1.8σ below trend (low inflation expectations), which is modestly supportive for long-duration sensitive sectors and generally benign for healthcare/medtech names like Edwards Lifesciences. With 184 minutes remaining there is ample time for continuation, and the move size (just over 2%) is meaningful but not so extended that a fade is likely already baked in. No reversal signals are noted. The absence of news does not disqualify the setup — it may reflect pre-earnings positioning or sector rotation. Key risks: no catalyst confirmation means the move could stall if buyers are exhausted, and the macro read is indirect for this ticker. Overall this is a modest momentum continuation setup with no strong fade trigger, warranting a probability just above the neutral threshold.

  137. !Jul 29, 12:41 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    EW is up 2.08% intraday with no attributable headline, suggesting organic institutional flow rather than a news-driven pop that might fade quickly. The macro context shows T10YIE at 1.8σ below trend (low inflation expectations), which is modestly supportive for long-duration sensitive sectors and generally benign for healthcare/medtech names like Edwards Lifesciences. With 184 minutes remaining there is ample time for continuation, and the move size (just over 2%) is meaningful but not so extended that a fade is likely already baked in. No reversal signals are noted. The absence of news does not disqualify the setup — it may reflect pre-earnings positioning or sector rotation. Key risks: no catalyst confirmation means the move could stall if buyers are exhausted, and the macro read is indirect for this ticker. Overall this is a modest momentum continuation setup with no strong fade trigger, warranting a probability just above the neutral threshold.

  138. ?Jul 29, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.

  139. ?Jul 29, 7:02 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $6.90 cash available; close=$83.68.

  140. ?Jul 28, 6:05 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.

  141. ?Jul 28, 6:05 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $6.28 cash available; close=$83.68.

  142. ?Jul 28, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.

  143. ?Jul 28, 7:04 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $5.71 cash available; close=$83.04.

  144. ?Jul 28, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $15.08 cash available; close=$84.55.

  145. ?Jul 27, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    Edwards Lifesciences (EW) is a well-established medical device leader in structural heart disease with a historically solid balance sheet and durable competitive moat. The 11.7% pullback from the 30-day high appears to be driven primarily by pre-earnings uncertainty (Q2 results imminent) rather than any confirmed fundamental deterioration, as the single news headline is neutral in sentiment and no adverse SEC filings are present. The macro environment — a flattening yield curve (T10Y2Y at 1.8σ below trend) — modestly favors defensive healthcare names, though it is not a strong tailwind catalyst.

  146. ▢Jul 1, 8:00 PMjournal

    options_momentum opened long 100 @ $3.72

  147. ▣Jun 29, 8:00 PMjournalstop

    options_momentum closed long 100 @ $2.15 (-$82.39)

    Stop: premium $2.15 ≤ trailing floor $2.23 (peak $2.97 × 0.75)

  148. ▢Jun 28, 8:00 PMjournal

    options_momentum opened long 100 @ $2.97

  149. ▣May 27, 8:00 PMjournalstop

    options_momentum closed long 200 @ $2.96 (-$42.38)

    Stop: premium $2.96 ≤ trailing floor $2.98 (peak $3.98 × 0.75)

  150. ▢May 21, 8:00 PMjournal

    options_momentum opened long 200 @ $3.17

← Back to dashboard